Stergiou
Principal executive officer pay for Stergiou, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
SELLAS Life Sciences Group, Inc. (SLS) FY2022–FY2025
Aligned: paid up as stock roseCAP $667,297→$4,426,030 while $100 invested went $42.68→$159.75
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $2.0M | $667,297 |
| FY2023 | $1.8M | $801,284 |
| FY2024 | $1.2M | $1.3M |
| FY2025 | $1.9M | $4.4M |
The company's "$100 invested" index ran $42.68 at FY2022 → $159.75 by FY2025 — an annualized return of 55.3%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 55.3%/yr at SLS ( FY2022–FY2025). See the CEO track-record ranking for context.